- In March 2024, ViiV Healthcare announced that its gene-editing therapy, EBT-101, received fast-track designation from the FDA. This development underscores ViiV Healthcare’s commitment to pioneering innovative treatments aimed at achieving a functional cure for HIV by targeting and editing the viral genome.
- In August 2023, Aurobindo Pharma unveiled a pediatric HIV triple combination product tailored for children in low- and middle-income countries. This initiative highlights the company’s focus on improving pediatric HIV care accessibility and addressing the specific needs of vulnerable populations in resource-limited settings.
- In December 2022, Gilead Sciences received FDA approval for lenacapavir (brand name Sunlenca), a first-in-class capsid inhibitor for treating multi-drug resistant HIV. This approval marked a significant milestone in HIV treatment options.
- In October 2024, Gilead Sciences signed agreements with six generic drug manufacturers to produce affordable versions of its HIV prevention medication, lenacapavir, for 120 low- and lower-middle-income countries. This initiative aims to enhance global access to HIV prevention.
- In April 2023, UC Davis Health researchers deployed CAR T cell therapy to treat patients suffering from HIV, leveraging immunotherapy to stimulate the immune system and provide a novel approach to HIV treatment. This advancement highlights the growing integration of cutting-edge cellular therapies in managing chronic viral infections and represents a promising direction in HIV research and care.
